In the ASSESS study [23], we observed high concordance of mutation status between matched biopsy/cytology and plasma samples, suggesting that circulating free tumor-derived DNA (ctDNA) can be isolated from the plasma or serum and could serve as a feasible sample for real-world EGFR mutation analysis. Here, EGFR is linked to neoplasm.